Quality control of NK cells produced ex vivo for malignant neoplasm therapy

The process of transferring the technology for obtaining a drug from the laboratory to production and, then, to the clinical practice is always a very complicated and time-consuming way, requiring many adaptation solutions. Regarding biomedical cell products (BMCP), this is even a more complex process, requiring large-scale expansion of procedures to obtain clinically significant numbers of cells, adaptation to reagents and equipment, and establishment of safety parameters for reagents, equipment and the final product. Nevertheless